肺动脉高压治疗新策略

Title:Novel Strategies in the Treatment of Pulmonary Arterial Hypertension

Volume: 17 Issue: 7

Author(s): Rosalinda Madonna, Nino Cocco

Affiliation:

关键词: 内皮素受体拮抗剂；PDE-5抑制剂；前列腺素；肺动脉高压。

摘要: Pulmonary arterial hypertension (PAH) is a pathophysiological condition characterized by increased pulmonary vascular resistance (PVR), initially due to abnormal pulmonary vasoconstriction in response to endothelial injury. Recent studies confirmed the key role of endothelin (ET)-1 in the vasoconstriction and remodeling of pulmonary microcirculation during PAH. In responders patients, classical treatments for PAH are prostanoids, phosphodiesterase (PDE)-5 inhibitors and endothelin receptor antagonists (ERAs), which target prostaglandin I2, nitric oxide and endothelin pathways, respectively. Randomised, placebo-controlled trials have shown that ERAs improves haemodynamic parameters of the pulmonary circulation, functional capacity and clinical outcome in patients affected by PAH. Here, we will review the definition, classification and pathophysiology of PH. Furthermore, we will provide an up-to-date overview of currently recommended diagnostic and therapeutic work-up in PAH.

Cite this article as:

Rosalinda Madonna, Nino Cocco , Novel Strategies in the Treatment of Pulmonary Arterial Hypertension, Current Drug Targets 2016; 17 (7) . https://dx.doi.org/10.2174/1389450116666150722140424